))
Revolutionizing RNA therapeutics - Avidity Biosciences
Manage episode 435213457 series 3594249
コンテンツは RTW Investments, LP, RTW Investments, and LP によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、RTW Investments, LP, RTW Investments, and LP またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Sarah Boyce from Avidity Biosciences and Piratip Pratumsuwan from RTW Investments explore the strategic decisions and innovations that have driven Avidity's success. They cover her approach to overcoming the challenges of scaling a biotech company, the impact of Avidity’s groundbreaking work on treating rare genetic disorders, and Sarah’s vision for the future of RNA-based therapies.
PODCAST TEAM
Producer: Devon Leaver
Technical Director: Joseph Sebring
Editor: Dominique Guerra
Featuring: Sarah Boyce, President and CEO of Avidity Biosciences, and Piratip Pratumsuwan, Managing Director; Research Analyst at RTW Investments.
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
CHAPTERS
00:00 - Introducing Sarah Boyce and Piratip Pratumsuwan
01:09 - Avidity Biosciences: Pioneering RNA therapeutics
02:20 - Joining Avidity: A bold decision
03:55 - Navigating challenges and embracing opportunities
12:00 - FSHD and Fortitude
18:21 - Looking Ahead: The future of RNA therapeutics
20:10 - Championing women in biotechnology
21:43 - Credits and disclaimer
DISCLAIMER
This interview and testimonial was given by Sarah Boyce, CEO of Avidity Biosciences, a company in which RTW has made an equity investment on behalf of its managed funds. No compensation was provided to Ms. Boyce.
2 つのエピソード
シェア
